MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

ROS1 tyrosine kinase inhibitors (TKI) provide significant benefit in lung adenocarcinoma patients with ROS1 fusions. However, as observed with all targeted therapies, resistance arises. Detecting mechanisms of acquired resistance (AR) is crucial to finding novel therapies and improve patient outcome...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2020-06, Vol.26 (12), p.2932-2945
Hauptverfasser:	Sato, Hiroki, Schoenfeld, Adam J, Siau, Evan, Lu, Yue Christine, Tai, Huichun, Suzawa, Ken, Kubota, Daisuke, Lui, Allan J W, Qeriqi, Besnik, Mattar, Marissa, Offin, Michael, Sakaguchi, Masakiyo, Toyooka, Shinichi, Drilon, Alexander, Rosen, Neal X, Kris, Mark G, Solit, David, De Stanchina, Elisa, Davare, Monika A, Riely, Gregory J, Ladanyi, Marc, Somwar, Romel
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!